Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 680M 597M 555M 509M 957M 65.46B 972M 6.59B 2.58B 32.18B 2.55B 2.5B 111B P/E 2026 *
10.4x
P/E 2027 * 10.6x
Enterprise Value 680M 597M 555M 509M 957M 65.46B 972M 6.59B 2.58B 32.18B 2.55B 2.5B 111B EV / Sales 2026 *
2.46x
EV / Sales 2027 * 2.05x
Free-Float
96.61%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rigel Pharmaceuticals, Inc.

1 day-0.22%
1 week-9.37%
Current month-6.08%
1 month+0.52%
3 months+21.29%
6 months-0.60%
Current year-14.22%
1 week 35.01
Extreme 35.0057
40.64
1 month 35.01
Extreme 35.0057
43.99
Current year 24.95
Extreme 24.95
49.1
1 year 19.51
Extreme 19.51
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 2014-11-20
Director of Finance/CFO 63 2018-05-28
Compliance Officer 58 2022-11-30
Director TitleAgeSince
Director/Board Member 71 1997-02-28
Director/Board Member 65 2014-11-20
Chairman 67 2022-04-30
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Free

Chief Technology Officer

24,400 0.1319%
6/22/26 Sell

Director

-2,500 0.0135%
6/17/26 Free

Compliance Officer

7,394 0.0400%
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%-9.37%+79.83%+189.29% 680M
+0.86%+1.43%+48.50%+160.39% 1,067B
+1.59%+4.09%+55.34%+53.96% 635B
+0.95%+1.91%+35.91%+81.14% 458B
+1.60%+6.25%+33.95%+29.84% 347B
-0.60%+1.52%+35.68%+39.76% 295B
-0.14%+0.60%+16.17%+17.53% 262B
+0.09%-2.82%-28.29%-41.71% 216B
+1.22%+2.66%+21.87%+59.73% 203B
-1.18%-3.70%+14.23%+66.51% 161B
Average +0.31%+0.26%+31.32%+65.64% 364.37B
Weighted average by Cap. +0.55%+1.95%+35.82%+77.70%

Financials

2026 *2027 *
Net sales 277M 243M 226M 207M 390M 26.64B 396M 2.68B 1.05B 13.1B 1.04B 1.02B 45.28B 331M 291M 270M 248M 466M 31.87B 473M 3.21B 1.25B 15.67B 1.24B 1.22B 54.17B
Net income 70.19M 61.65M 57.33M 52.61M 98.85M 6.76B 100M 681M 266M 3.32B 264M 258M 11.49B 79.07M 69.45M 64.58M 59.26M 111M 7.61B 113M 767M 300M 3.74B 297M 290M 12.94B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
26-07-24 US$36.74 -0.22% 485,299
26-07-23 US$36.82 -2.59% 383,198
26-07-22 US$37.80 -3.84% 331,743
26-07-21 US$39.31 -0.91% 456,768
26-07-20 US$39.67 -2.15% 363,057
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.74USD
Average target price
54.20USD
Spread / Average Target
+47.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock